Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
PIRAMAL ENTERPRISES | SUN PHARMA | PIRAMAL ENTERPRISES/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -36.5 | 133.5 | - | View Chart |
P/BV | x | 1.2 | 3.1 | 40.2% | View Chart |
Dividend Yield | % | 1.9 | 0.7 | 270.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PIRAMAL ENTERPRISES Mar-19 |
SUN PHARMA Mar-20 |
PIRAMAL ENTERPRISES/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,303 | 484 | 682.2% | |
Low | Rs | 1,797 | 315 | 570.1% | |
Sales per share (Unadj.) | Rs | 716.5 | 136.9 | 523.5% | |
Earnings per share (Unadj.) | Rs | 79.7 | 17.5 | 456.7% | |
Cash flow per share (Unadj.) | Rs | 107.9 | 26.0 | 414.9% | |
Dividends per share (Unadj.) | Rs | 28.00 | 4.00 | 700.0% | |
Dividend yield (eoy) | % | 1.1 | 1.0 | 109.7% | |
Book value per share (Unadj.) | Rs | 1,477.5 | 188.7 | 783.2% | |
Shares outstanding (eoy) | m | 184.45 | 2,399.26 | 7.7% | |
Bonus/Rights/Conversions | IS | - | - | ||
Price / Sales ratio | x | 3.6 | 2.9 | 121.9% | |
Avg P/E ratio | x | 32.0 | 22.9 | 139.7% | |
P/CF ratio (eoy) | x | 23.6 | 15.4 | 153.8% | |
Price / Book Value ratio | x | 1.7 | 2.1 | 81.5% | |
Dividend payout | % | 35.1 | 22.9 | 153.3% | |
Avg Mkt Cap | Rs m | 470,292 | 958,864 | 49.0% | |
No. of employees | `000 | 7.8 | 17.8 | 44.0% | |
Total wages/salary | Rs m | 22,504 | 63,624 | 35.4% | |
Avg. sales/employee | Rs Th | 16,899.4 | 18,490.6 | 91.4% | |
Avg. wages/employee | Rs Th | 2,877.7 | 3,582.6 | 80.3% | |
Avg. net profit/employee | Rs Th | 1,879.9 | 2,357.6 | 79.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 132,153 | 328,375 | 40.2% | |
Other income | Rs m | 3,128 | 6,360 | 49.2% | |
Total revenues | Rs m | 135,281 | 334,735 | 40.4% | |
Gross profit | Rs m | 66,290 | 69,898 | 94.8% | |
Depreciation | Rs m | 5,202 | 20,528 | 25.3% | |
Interest | Rs m | 44,097 | 3,027 | 1,456.7% | |
Profit before tax | Rs m | 20,119 | 52,702 | 38.2% | |
Minority Interest | Rs m | 3,194 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 8,611 | 8,228 | 104.7% | |
Profit after tax | Rs m | 14,701 | 41,868 | 35.1% | |
Gross profit margin | % | 50.2 | 21.3 | 235.7% | |
Effective tax rate | % | 42.8 | 15.6 | 274.2% | |
Net profit margin | % | 11.1 | 12.8 | 87.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 122,742 | 316,542 | 38.8% | |
Current liabilities | Rs m | 310,810 | 157,064 | 197.9% | |
Net working cap to sales | % | -142.3 | 48.6 | -293.0% | |
Current ratio | x | 0.4 | 2.0 | 19.6% | |
Inventory Days | Days | 23 | 88 | 26.4% | |
Debtors Days | Days | 39 | 105 | 37.1% | |
Net fixed assets | Rs m | 116,904 | 243,102 | 48.1% | |
Share capital | Rs m | 369 | 2,399 | 15.4% | |
"Free" reserves | Rs m | 272,161 | 450,245 | 60.4% | |
Net worth | Rs m | 272,530 | 452,645 | 60.2% | |
Long term debt | Rs m | 270,196 | 20,289 | 1,331.7% | |
Total assets | Rs m | 856,261 | 682,525 | 125.5% | |
Interest coverage | x | 1.5 | 18.4 | 7.9% | |
Debt to equity ratio | x | 1.0 | 0 | 2,211.9% | |
Sales to assets ratio | x | 0.2 | 0.5 | 32.1% | |
Return on assets | % | 6.9 | 6.6 | 104.4% | |
Return on equity | % | 5.4 | 9.2 | 58.3% | |
Return on capital | % | 12.4 | 11.2 | 110.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 15,200 | 74,219 | 20.5% | |
Fx outflow | Rs m | 4,889 | 27,964 | 17.5% | |
Net fx | Rs m | 10,312 | 46,255 | 22.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -115,975 | 65,548 | -176.9% | |
From Investments | Rs m | -8,265 | -25,888 | 31.9% | |
From Financial Activity | Rs m | 107,525 | -57,151 | -188.1% | |
Net Cashflow | Rs m | -16,650 | -13,857 | 120.2% |
Indian Promoters | % | 52.9 | 63.7 | 83.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 4.0 | 5.1 | 78.0% | |
FIIs | % | 26.6 | 23.0 | 115.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 16.5 | 8.3 | 198.8% | |
Shareholders | 93,274 | 133,026 | 70.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare PIRAMAL ENTERPRISES With: IPCA LABS NOVARTIS DR. DATSONS LABS PROCTER & GAMBLE HEALTH GSK PHARMA
Compare PIRAMAL ENTERPRISES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended June 2020, PIRAMAL ENTERPRISES has posted a net profit of Rs 5 bn (up 22.1% YoY). Sales on the other hand came in at Rs 29 bn (down 16.2% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.
For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More